Viewing nowCombinationSevirol Tablet 5/20 mg
Olmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.

MFDS item code 201405503 · Approved 2014.11.25 · Insurance code 646003860
Treatment of essential hypertension not controlled by monotherapy
This medication is used in the treatment of patients with essential hypertension whose blood pressure is not adequately controlled with monotherapy of amlodipine or olmesartan medoxomil. It helps effectively control blood pressure and reduce the risk of complications due to hypertension. As it plays an important role in hypertension management, consistent intake is required. This medication stabilizes blood pressure by either dilating blood vessels or inhibiting increases in blood pressure, contributing to overall cardiovascular health improvement. When used safely, it is effective for the treatment of hypertension.
Administer 1 tablet of this medicine once daily with water, with or without food. It is recommended to take it at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood-pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. This medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine must not be administered to patients with severe hepatic impairment. (See section 2, Patients who must not be administered this medicine, under Precautions for Use.) ∘ Older adults: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.
∘ Children: The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, and cessation of use should occur immediately upon confirmation of pregnancy. It should not be used in patients who are allergic to the ingredients contained in this medication, pregnant or breastfeeding, have severe liver disease, aortic stenosis, biliary obstruction, are undergoing kidney dialysis, in a state of shock, or have certain diabetes conditions. Patients with insufficient body fluids or salts may experience low blood pressure; hence they should start the medication with careful monitoring of their condition. Caution should be exercised as sudden vasodilation may cause low blood pressure, especially in patients with severe aortic stenosis. For patients with severe coronary artery disease, the risk of angina or myocardial infarction may increase when this drug is used, requiring careful consideration. Patients with heart failure should use this medication carefully, and patients with impaired kidney function should monitor for changes in kidney function while using this medication. Patients with reduced liver function should be cautious as metabolism of this drug may slow down when taken. During use of this medication, side effects such as dizziness, headache, hypotension, orthostatic hypotension, edema, dyspepsia, skin rash, and more may occur. This medication may have serious effects on the fetus during pregnancy, so women who are planning to conceive or are currently pregnant must consult a doctor. If breastfeeding, the medication may be transmitted through breast milk and could produce side effects in infants, necessitating either cessation of breastfeeding or the drug. Safety and efficacy in children and adolescents under 18 years has not been established and is not recommended. In elderly patients, due to impaired kidney and liver function, drug concentrations in the body may increase; therefore, starting at low doses and careful monitoring is advisable. In case of overdose, symptoms such as low blood pressure and heart rhythm irregularities may occur, and immediate notification to medical staff and appropriate treatment is required. This medication should be stored in a tightly closed container away from moisture, heat, and direct sunlight, and should not be transferred to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture from entering, ideally at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness for a longer period.
White round film-coated tablet
28 tablets (14 tablets/PTP x 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.